Index

Abrahamsen, B., Hangaard, J., Horn, H.C., Hansen, T.B., Gregersen, G., Hansen-Nord, M., Vahl, N., Junker, P., Andersen, M. & Hagen, C. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies: 273

Aglietti, M.C. *see* Laureti, S.

Aguiar-Oliveira, M.H. *see* Gleeson, H.K.

Aguiar-Oliveira, M.H. *see* Salvatori, R.

Ahmed, S.F., Tucker, P., Mushtaq, T., Wallace, A.M., Williams, D.M. & Hughes, I.A. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone: 185

Akalin, A., Colak, Ö., Alatas, Ö. & Efe, B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism: 125

Akalin, S. *see* Koc, M.

Åkerström, G. *see* Correa, P.

Akkaya, V. *see* Erten, Y.

Akpinar, I. *see* Koc, M.

Al-Mrayat, M. *see* Johnston, D.G.

Alatas, Ö. *see* Akalin, A.

Albareda, M. *see* Webb, S.M.

Albertsson-Wikland, K. *see* Bjarnason, R.

Alexander, E.K., Robinson, M., Staniec, M. & Dluhy, R.G. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome: 825

Álvarez, P. *see* Leal-Cerro, A.

Amato, G. *see* Carella, C.

Amato, P. *see* Arroyo, A.

Amino, N. *see* Izumi, Y.

Andersen, M. *see* Abrahamsen, B.

Andersson, S. *see* Kajantie, E.

Andrew, R. *see* Walker, B.R.

Angelica, M. *see* Giampaolo, B.

Antonini, S.R.R., Latronico, A.C., Elias, L.L.K., Cukiert, A., Machado, H.R., Liberman, B., Mendonca, B.B., Moreira, A.C. & Castro, M. Glucocorticoid receptor gene polymorphisms in ACTH-secreting pituitary tumours: 657

Antonio, S. *see* Giampaolo, B.

Aranda, I. *see* Boix, E.

Arends, N.J.T., Lip, W.V.D., Robben, S.G.F. & Hokken-Koelega, A.C.S. MRI findings of the pituitary gland in short children born small for gestational age (SGA) in comparison with growth hormone-deficient (GHD) children and children with normal stature: 719

Arnaldi, G. *see* Francucci, C.M.

Arnqvist, H.J. *see* Ekman, B.

Arroyo, A., Pernasetti, F., Vasilyev, V.V., Amato, P., Yen, S.S.C. & Mellon, P.L. A unique case of combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C) associated with normal height and absent puberty: 283

Arvat, E. *see* Broglio, F.

Arvat, E. *see* Laureti, S.

Ashley, S. *see* Brada, M.

Astorga, R. *see* Webb, S.M.

Badia, X. *see* Webb, S.M.

Bakker, B., Kempers, M.J.E., De Vijlder, J.J.M., Van Tijn, D.A., Wiedijk, B.M., Van Bruggen, M. & Vulsma, T. Dynamics of the plasma concentrations of TSH, FT4 and T3 following thyroxine supplementation in congenital hypothyroidism: 529

Balen, A.H. *see* Wijeyaratne, C.N.

Bali, M. *see* Erten, Y.

Ban, Y., Davies, T.F., Greenberg, D.A., Concepcion, E.S. & Tomer, Y. The influence of human leucocyte antigen (HLA) genes on autoimmune thyroid disease (AITD): results of studies in HLA-DR3 positive AITD families: 81

Banerjee, K. *see* Bjarnason, R.

Barker, D.J.P. *see* Kajantie, E.

de A. Barretto, E.S. *see* Gleeson, H.K.

Barretto-Filho, J.A.S. *see* Gleeson, H.K.

Bartalena, L. *see* Bogazzi, F.

Barth, J.H. *see* Wijeyaratne, C.N.

Basaria, S., Nguyen, T., Rosenson, R.S. & Dobs, A.S. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women: , 209

Basu, M., Sawhney, R.C., Kumar, S., Pal, K., Prasad, R. & Selvamurthy, W. Glucocorticoids as prophylaxis against acute mountain sickness: 761

Baudin, E. *see* Faggiano, A.

Baudin, E. *see* Lamarre-Cliche, M.

Bayón, C. *see* Díez, J.J.

Belchetz, P.E. *see* Wijeyaratne, C.N.

Belton, N.R. *see* Walker, B.R.

Bengtsson, B.-Å. *see* Leonsson, M.

Benso, A. *see* Broglio, F.

Bercovici, J.P., Machelon, V., Gaudin-Nome, F., Roudaut, N., Conan-Charlet, V., Leroy, J.P., Sensebe, L. & Kerlan, V. Hodgkin's disease masquerading as fibrous thyroiditis: potential role of cytokines in *in vivo* and *in vitro* studies: 691

Bergmann, A. *see* Morgenthaler, N.G.

Bernardi, S. *see* Matarese, G.

© 2002 Blackwell Science Ltd

Besser, G.M. *see* Mukhopadhyay, B.
Besser, G.M. *see* Janmohamed, S.
Besser, G.M. *see* Kaltsas, G.A.
Bidart, J.M. *see* Faggiano, A.
Billaud, E. *see* Lamarre-Cliche, M.
Bjarnason, R., Banerjee, K., Rose, S.J., Rosberg, S., Metherell, L., Clark, A.J.L., Albertsson-Wikland, K. & Savage, M.O. Spontaneous growth hormone secretory characteristics in children with partial growth hormone insensitivity, 357
Blackhurst, G., Strachan, M.W., Collie, D., Gregor, A., Statham, P.F.X. & Seckl, J.E.R. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy, 401
Blair, J.C., Mohan, U., Larcher, V.F., Rajanayagam, O., Burrin, J.M., Perry, L.A., Grossman, A.B., Chatterjee, V.K.K. & Savage, M.O. Neonatal thyrotoxicosis and maternal infertility in thyroid hormone resistance due to a mutation in the TRβ gene (M313T), 405
Bocca, L. *see* Giusti, M.
Bodur, H. *see* Erten, Y.
Boemi, S. *see* Cianfarani, S.
Bogazzi, F. *see* Manetti, L.
Bogazzi, F., Manetti, L., Bartalena, L., Gasperi, M., Grasso, L., Cecconi, E. & Martino, E. Thyroid vascularity is increased in patients with active acromegaly: 65
Boguszewski, C.L. *see* Wirén, L.
Boix, E., Picó, A., Pinedo, R., Aranda, I. & Kovacs, K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour: 131
Borboli, N. *see* Kaltsas, G.A.
Boscherini, B. *see* Cianfarani, S.
Brada, M., Ashley, S., Ford, D., Traish, D., Burchell, L. & Rajan, B. Cerebrovascular mortality in patients with pituitary adenoma: 713
Brismar, K. *see* Halldin, M.U.
Brismar, K. *see* Unden, A.-L.
Brogioni, S. *see* Manetti, L.
Broglio, F., Benso, A., Gottero, C., Prodam, F., Grottoli, S., Tassone, F., Maccario, M., Casanueva, F.F., Dieguez, C., Deghenghi, R., Ghigo, E. & Arvat, E. Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans: 265
Brommer, E. *see* Schmidt, A.
Bronstein, M.D. *see* Glezer, A.
Bruno, G.A. *see* Martina, V.
Bülow, I. *see* Knudsen, N.
Buongiorno, A. *see* Sbraccia, P.
Buonocore, G. *see* Massafra, C.
Burchell, L. *see* Brada, M.
Burrin, J.M. *see* Blair, J.C.
Cabrol, S. *see* Meas, T.
Caillou, B. *see* Faggiano, A.
Canbakan, B. *see* Erten, Y.
Cancrini, C. *see* Matarese, G.
Candeloro, P. *see* Laureti, S.
Carbonella, M. *see* Manzella, D.
Carella, C., Mazziotti, G., Rotondi, M., Del Buono, A., Zito, G., Sorvillo, F., Manganella, G., Santini, L. & Amato, G. Iodized salt improves the effectiveness of L-thyroxine therapy after surgery for nontoxic goitre: a prospective and randomized study: 507
Carmina, E. & Lobo, R.A. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women: 231
Casanueva, F.F. *see* Broglio, F.
Casanueva, F.F. *see* Leal, A.
Casanueva, F.F. *see* Leal-Cerro, A.
Castelli-Gattinara, G. *see* Matarese, G.
Castro, M. *see* Antonini, S.R.R.
Catalá, M. *see* Webb, S.M.
Cecconi, E. *see* Bogazzi, F.
Cecconi, E. *see* Manetti, L.
Chakravarty, A. *see* Schmidt, A.
Chang, T.-J., Tsai, M.-H., Jiang, Y.-D., Lee, B., Lee, K.-C., Lin, J.-Y., Chiu, K.C., Tai, T.-Y. & Chuang, L.-M. The Arg16Gly polymorphism of human β2-adrenoreceptor is associated with type 2 diabetes in Taiwanese people: 685
Chatelain, P. *see* Yuen, K.
Chatterjee, V.K.K. *see* Blair, J.C.
Chau, W.-F. *see* Saravanan, P.
Chen, C.-H. *see* Hsieh, C.-J.
Chen, J.-F. *see* Hsieh, C.-J.
Chen-Hsiong C. *see* Ching-Jung H.
Chevenne, D. *see* Meas, T.
Chew, S.L. *see* Mukhopadhyay, B.
Chew, S.L. *see* Janmohamed, S.
Chien, W.-Y. *see* Hsieh, C.-J.
Chiu, K.C. *see* Chang, T.-J.
Cho, B.Y. *see* Chung, J.-K.
Christiansen, J.S. *see* Hansen, T.K.
Christiansen, J.S. *see* Nørrelund, H.
Chuang, L.-M. *see* Chang, T.-J.
Chung, J.-K., Park, Y.J., Kim, T.Y., So, Y., Kim, S.-K., Park, D.J., Lee, D.S., Lee, M.C. & Cho, B.Y. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation: 215
Cianfarani, S., Tondinelli, T., Spadoni, G.L., Scirè, G., Boemi, S. & Boscherini, B. Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? 161

Clark, A.J.L. *see* Bjarnason, R.
Clayton, P.E. *see* Gleeson, H.K.
Clayton, P.E. *see* Trueman, J.A.
Colak, Ö. *see* Akalin, A.
Colantuoni, V. *see* Vaccaro, O.
Collie, D. *see* Blackhurst, G.
Conan-Charlet, V. *see* Bercovici, J.P.
Concepcion, E.S. *see* Ban, Y.
Connell, J.M.C. *see* McCallum, R.W.
Cook, D. *see* Yuen, K.
Cordido, F. *see* Leal-Cerro, A.
Correa, P., Åkerström, G. & Westin, G. Underexpression of *Gcm2*, a master regulatory gene of parathyroid gland development, in adenomas of primary hyperparathyroidism: 501
Corsaro, A. *see* Giusti, M.
van Coeverden, S.C.C.M., Netelenbos, J.C., de Ridder, C.M., Roos, J.C., Popp-Snijders, C. & Delemarre-van de Waal, H.A. Bone metabolism markers and bone mass in healthy pubertal boys and girls: 107
Cremades, C. *see* Ruíz-Giardín, J.M.
Crofton, P.M. *see* Doherty, C.P.
Cukiert, A. *see* Antonini, S.R.R.
Cusick, C.F. *see* Trueman, J.A.
Cutting, W.A. *see* Doherty, C.P.
Czernichow, P. *see* Meas, T.
Czirják, S. *see* Kaltsas, G.A.
D'Adamo, M. *see* Sbraccia, P.
D'Alva, C.B. *see* Glezer, A.
Dacou-Voutetakis, C. *see* Manoli, I.
Damber, L. *see* Rasmuson, T.
Dattani, M.T. GH deficiency might be associated with normal height in PROP1 deficiency: 157
Davies, M., Fraser, W.D. & Hosking, D.J. The management of primary hyperthyroidism: 145
Davies, T.F. *see* Ban, Y.
Dayan, C.M. *see* Saravanan, P.
De Felice, C. *see* Massafra, C.
De Meyts, P. *see* Schmidt, A.
De Vijlder, J.J.M. *see* Bakker, B.
Deghenghi, R. *see* Broglio, F.
Del Buono, A. *see* Carella, C.
Delemarre-van de Waal, H.A. *see* van Coeverden, S.C.C.M.
Demers, L. *see* Whipple, T.
Deyneli, O. *see* Koc, M.
Di Daniele, N. *see* Sbraccia, P.
Di Giacomo, A. *see* Matarese, G.
Diamant, M. *see* Schaap, J.
Dieguez, C. *see* Broglio, F.
Dieguez, C. *see* Leal, A.
Dieguez, C. *see* Leal-Cerro, A.
Díez, J.J., Hernanz, A., Medina, S., Bayón, C. & Iglesias, P. Serum concentrations of tumour necrosis factor-alpha (TNF-α) and soluble TNF-α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function: 515
Dixon, J.B. & O'Brien, P.E. Neck circumference a good predictor of raised insulin and free androgen index in obese premenopausal women: changes with weight loss: 769
Dluhy, R.G. *see* Alexander, E.K.
Dobs, A.S. *see* Basaria, S.
Doherty, C.P., Crofton, P.M., Sarkar, M.A.K., Shakur, M.S., Wade, J.C., Kelnar, C.J.H., Elmlinger, M.W., Ranke, M.B. & Cutting, W.A. Malnutrition, zinc supplementation and catch-up growth: changes in insulin-like growth factor I, its binding proteins, bone formation and collagen turnover: 391
Dominiczak, A.F. *see* McCallum, R.W.
Donckier, J.E. *see* Rosière, A.
van Doorn, J. *see* Kamp, G.A.
Dunger, D. *see* Yuen, K.
Dunkel, L. *see* Kajantie, E.
Dunne, F. *see* Toescu, V.
Eckardstein, S.V., Schmidt, A., Kamischke, A., Simoni, M., Gromoll, J. & Nieschlag, E. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception: 647
Efe, B. *see* Akalin, A.
Efstathiou, S.P., Tsiakou, A.G., Tsioulos, D.I., Zacharos, I.D., Mitromaras, A.G., Mastorantonakis, S.E., Panagiotou, T.N. & Mountokalakis, T.D. A mortality prediction model in diabetic ketoacidosis: 595
Ekman, B., Öhman, P.K., Arnqvist, H.J., Lindström, T. & Nyström, F.H. Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin–angiotensin–aldosterone system: 473
Elias, L.L.K. *see* Antonini, S.R.R.
Elmlinger, M.W. *see* Doherty, C.P.
Elofsson, S. *see* Unden, A.-L.
Eriksson, J. *see* Kajantie, E.
Ernst, Y.J. *see* Rosière, A.
Ersoz, H.O. *see* Koc, M.
Erten, Y., Bodur, H., Şahiner, Ş., Tolunay, O., Akkaya, V., Canbakan, B. & Bali, M. Antineutrophil cytoplasmic antibody associated vasculitis and rapidly progressive glomerulonephritis as a complication of propylthiouracil therapy: 699
Esaa, S. *see* Lanes, R.
Eustatia-Rutten, C.F.A. *see* Schaap, J.
Faggiano, A., Talbot, M., Lacroix, L., Bidart, J.M., Baudin, E., Schlumberger, M. & Caillou, B. Differential expression of

galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia: 813
Fairfield, W.P., Sesmilo, G., Katznelson, L., Pulaski, K., Freda, P.U., Stavrou, S., Kleinberg, D. & Klibanski, A. Effects of a growth hormone receptor antagonist on bone markers in acromegaly: 385
Falorni, A. *see* Laureti, S.
Federici, M. *see* Sbraccia, P.
Feldt-Rasmussen, U. *see* Sneppen, S.B.
Fenne, B.D. *see* Schmidt, A.
Fisker, S. *see* Hansen, T.K.
Florio, T. *see* Giusti, M.
Ford, D. *see* Brada, M.
Forsén, T. *see* Kajantie, E.
Forsling, M.L. & Williams, A.J. The effect of exogenous melatonin on stimulated neurohypophysial hormone release in man: 615
Foster, P. *see* Trueman, J.A.
Francucci, C.M., Pantanetti, P., Garrapa, G.G., Massi, F., Arnaldi, G. & Mantero, F. Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma: 587
Fraser, W.D. *see* Davies, M.
Freda, P.U. *see* Fairfield, W.P.
Frölich, M. *see* Kamp, G.A.
Fryklund, L. *see* Yuen, K.
Gaia, D. *see* Martina, V.
García de la Torre, N., Wass, J.A.H. & Turner, H.E. Antiangiogenic effects of somatostatin analogues: 425
Garcia-Mayor, R.V. *see* Leal, A.
Garrapa, G.G. *see* Francucci, C.M.
Gasperi, M. *see* Bogazzi, F.
Gasperi, M. *see* Manetti, L.
Gaudin-Nome, F. *see* Bercovici, J.P.
Gaztambide, S. *see* Webb, S.M.
Genovesi, M. *see* Manetti, L.
Ghigo, E. *see* Broglio, F.
Ghigo, E. *see* Laureti, S.
Giampaolo, B., Angelica, M. & Antonio, S. Chromogranin 'A' in normal subjects, essential hypertensives and adrenalectomized patients: 41
Gilchrist, F.J., Murray, R.D. & Shalet, S.M. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults: 363
Gill, M.S. *see* Gleeson, H.K.
Gimenez-Roqueplo, A.-P. *see* Lamarre-Cliche, M.
Gioia, D. *see* Massafra, C.
Giordano, R. *see* Laureti, S.
Giusti, M., Bocca, L., Florio, T., Corsaro, A., Spaziante, R., Schettini, G. & Minuto, F. *In vitro* effect of human recombinant leptin and expression of leptin receptors on growth hormone-secreting human pituitary adenomas: 449
Gleeson, H.K., Souza, A.H.O., Gill, M.S., Wieringa, G.E., de A. Barretto, E.S., Barretto-Filho, J.A.S., Shalet, S.M., Aguiar-Oliveira, M.H. & Clayton, P.E. Lipid profiles in untreated severe congenital isolated growth hormone deficiency through the lifespan: 89
Glezer, A., D'Alva, C.B., Salgado, L.R., Musolino, N.R., Serafini, P., Vieira, J.G. & Bronstein, M.D. Pitfalls in pituitary diagnosis: peculiarities of three cases: 135
Gluckman, P. *see* Yuen, K.
Gogas-Yavuz, D. *see* Koc, M.
Gottero, C. *see* Broglio, F.
Grasso, L. *see* Bogazzi, F.
Grasso, L. *see* Manetti, L.
Greenberg, D.A. *see* Ban, Y.
Greenwood, R. *see* Saravanan, P.
Gregersen, G. *see* Abrahamsen, B.
Gregor, A. *see* Blackhurst, G.
Grella, R. *see* Manzella, D.
Gromoll, J. *see* Eckardstein, S.V.
Grossman, A.B. *see* Blair, J.C.
Grossman, A.B. *see* Janmohamed, S.
Grossman, A.B. *see* Kaltsas, G.A.
Grossman, A.B. *see* Kaltsas, G.A.
Grottoli, S. *see* Broglio, F.
Gueorguiev, M. *see* Kaltsas, G.A.
Gunczler, P. *see* Lanes, R.
Gustafsson, J. *see* Halldin, M.U.
Haber, R.S., Kim, C.K. & Inabnet, W.B. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperarathyroidism: comparison with ^{99m}technetium sestamibi scintigraphy: 241
Hackeng, W. *see* Kamp, G.A.
Hagen, C. *see* Abrahamsen, B.
Hahn, E.G. *see* Seifarth, C.
Hall, C.M. *see* Trueman, J.A.
Halldin, M.U., Brismar, K., Tuvemo, T. & Gustafsson, J. Insulin sensitivity and lipolysis in adolescent girls with poorly controlled type 1 diabetes: effect of anticholinergic treatment: 735
Halperin, I. *see* Webb, S.M.
Hangaard, J. *see* Abrahamsen, B.
Hansen, B. *see* Hansen, T.K.
Hansen, T.B. *see* Abrahamsen, B.
Hansen, T.K. *see* Nørrelund, H.
Hansen, T.K., Fisker, S., Hansen, B., Sørensen, H.H., Christiansen, J.S., Jørgensen, J.O.L. & Ørskov, H. Impact of GHBP interference on estimates of GH and GH pharmacokinetics: 779
Hansen-Nord, M. *see* Abrahamsen, B.

Hauache, O.M., Rocha, A.J., Maia Jr, A.C.M., Maciel, R.M.B. & Vieira, J.G.H. Screening for macroprolactinaemia and pituitary imaging studies: 327
Hedges, L. *see* Salvatori, R.
Hensen, J. *see* Seifarth, C.
Hernanz, A. *see* Díez, J.J.
Hidaka, Y. *see* Izumi, Y.
Hokken-Koelega, A.C.S. *see* Arends, N.J.T.
Horn, H.C. *see* Abrahamsen, B.
Hoshikawa, S. *see* Nakagawa, Y.
Hosking, D.J. *see* Davies, M.
Hosoda, H. *see* Nørrelund, H.
Hsieh, C.-J., Wang, P.-W., Wang, S.-T., Liu, R.-T., Tung, S.-C., Chien, W.-Y., Lu, Y.-C., Chen, J.-F., Chen, C.-H. & Kuo, M.-C. Serum leptin concentrations of patients with sequential thyroid function changes: 29
Hughes, I.A. *see* Ahmed, S.F.
Hulthe, J. *see* Leonsson, M.
Ichihara, K. *see* Izumi, Y.
Iglesias, P. *see* Díez, J.J.
Iitaka, M. *see* Minagawa, A.
Iitaka, M. *see* Morgenthaler, N.G.
Inabnet, W.B. *see* Haber, R.S.
Iovine, C. *see* Vaccaro, O.
Irving, R.J. *see* Walker, B.R.
Isidori, A. *see* Kaltsas, G.A.
Isidro, L. *see* Leal-Cerro, A.
Ito, S. *see* Nakagawa, Y.
Izumi, Y., Hidaka, Y., Tada, H., Takano, T., Kashiwai, T. Tatsumi, K.-I., Ichihara, K. & Amino, N. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis: 51
Jackson, J.E. *see* Turner, J.J.O.
Janmohamed, S., Grossman, A.B., Metcalfe, K., Lowe, D.G., Wood, D.F., Chew, S.L., Monson, J.P., Besser, G.M. & Plowman, P.N. Suprasellar germ cell tumours: specific problems and the evolution of optimal management with a combined chemoradiotherapy regimen: 487
Jiang, Y.-D. *see* Chang, T.-J.
Johannsson, G. *see* Leonsson, M.
Johannsson, G. *see* Wirén, L.
Johansson, L. *see* Rasmuson, T.
Johansson, R. *see* Rasmuson, T.
Johnston, D.G., Kearney, T., Robinson, S. & Al-Mrayat, M. Some elucidation of the mechanisms of vascular disease in hypopituitarism: 159
Jørgensen, J.O.L. *see* Hansen, T.K.
Jørgensen, J.O.L. *see* Nørrelund, H.
Jørgensen, T. *see* Knudsen, N.
Jung-Fu C. *see* Ching-Jung H.
Junker, P. *see* Abrahamsen, B.
Kahn, C.R. *see* Mauvais-Janis, F.
Kajantie, E., Phillips, D.I.W., Andersson, S., Barker, D.J.P., Dunkel, L., Forsén, T., Osmond, C., Tuominen, J., Wood, P.J. & Eriksson, J. Size at birth, gestational age and cortisol secretion in adult life: foetal programming of both hyper- and hypocortisolism? 635
Kaltsas, G.A., Kola, B., Borboli, N., Morris, D.G., Gueorguiev, M., Swords, F.M., Czirják, S., Kirschner, L.S., Stratakis, C.A., Korbonits, M. & Grossman, A.B. Sequence analysis of the *PRKAR1A* gene in sporadic somatotroph and other pituitary tumours: 443
Kaltsas, G.A., Mukherjee, J.J., Isidori, A., Kola, B., Plowman, P.N., Monson, J.P., Grossman, A.B. & Besser, G.M. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil: 169
Kameyama, K. *see* Minagawa, A.
Kamischke, A. *see* Eckardstein, S.V.
Kamp, G.A., Zwinderman, A.H., van Doorn, J., Hackeng, W., Frölich, M., Schönau, E. & Wit, J.M. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH: 315
Kanaka-Gantenbein, Ch. *see* Manoli, I.
Kangawa, K. *see* Nørrelund, H.
Kashiwai, T. *see* Izumi, Y.
Katayama, S. *see* Minagawa, A.
Katayama, S. *see* Morgenthaler, N.G.
Katznelson, L. *see* Fairfield, W.P.
Kearney, T. *see* Johnston, D.G.
Kelnar, C.J.H. *see* Doherty, C.P.
Kempers, M.J.E. *see* Bakker, B.
Kendall, M.J. *see* Toescu, V.
Keogh, M.A. & Wittert, G.A. Effect of cabergoline on thyroid function in hyperprolactinaemia: 699
Kerlan, V. *see* Bercovici, J.P.
Kiess, W. *see* Schmidt, A.
Kim, C.K. *see* Haber, R.S.
Kim, S.-K. *see* Chung, J.-K.
Kim, T.Y. *see* Chung, J.-K.
Kirschner, L.S. *see* Kaltsas, G.A.
Kitahama, S. *see* Minagawa, A.
Kleinberg, D. *see* Fairfield, W.P.
Klibanski, A. *see* Fairfield, W.P.
Knox, S. *see* Unden, A.-L.
Knudsen, N., Bülow, I., Laurberg, P., Perrild, H., Ovesen, L. & Jørgensen, T. Low goitre prevalence among users of oral contraceptives in a population sample of 3712 women: 71
Koc, M., Ersoz, H.O., Akpinar, I., Gogas-Yavuz, D., Deyneli, O. & Akalin, S. Effect of low- and high-dose levothyroxine on

thyroid nodule volume: a crossover placebo-controlled trial: 621
Kojima, M. *see* Nørrelund, H.
Kola, B. *see* Kaltsas, G.A.
Kola, B. *see* Kaltsas, G.A.
Koppeschaar, H.P.F. *see* Leal, A.
Korbonits, M. *see* Kaltsas, G.A.
Kovacs, K. *see* Boix, E.
Kulkarni, R.N. *see* Mauvais-Jarvis, F.
Kumar, S. *see* Basu, M.
Kuo, M.-C. *see* Hsieh, C.-J.
Lacroix, L. *see* Faggiano, A.
Ladenson, P.W. Psychological wellbeing in patients: 575
Lage, M. *see* Leal, A.
Lamarre-Cliche, M., Gimenez-Roqueplo, A.-P., Billaud, E., Baudin, E., Luton, J.-P. & Plouin, P.-F. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma: 629
Lanes, R., Gunczler, P., Esaa, S. & Weisinger, J.R. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study: 725
Larcher, V.F. *see* Blair, J.C.
Larsson, L.-G. *see* Rasmuson, T.
Latronico, A.C. *see* Antonini, S.R.R.
Laurberg, P. *see* Knudsen, N.
Laureti, S., Candeloro, P., Aglietti, M.C., Giordano, R., Arvat, E., Ghigo, E., Santeusanio, F. & Falorni, A. Dehydroepiandrosterone, 17α-hydroxyprogesterone and aldosterone responses to the low-dose (1 μg) ACTH test in subjects with preclinical adrenal autoimmunity: 677
Lauro, D. *see* Sbraccia, P.
Lauro, R. *see* Sbraccia, P.
Leal, A., Lage, M., Popovic, V., Torres, E., Koppeschaar, H.P.F., Paramo, C., Micic, D., Garcia-Mayor, R.V., Dieguez, C. & Casanueva, F.F. A single growth hormone (GH) determination is sufficient for the diagnosis of GH-deficiency in adult patients using the growth hormone releasing hormone plus growth hormone releasing peptide-6 test: 377
Leal-Cerro, A., Soto, A., Martínez, M.A., Álvarez, P., Isidro, L., Casanueva, F.F., Dieguez, C. & Cordido, F. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome: 745
Lee, B. *see* Chang, T.-J.
Lee, D.S. *see* Chung, J.-K.
Lee, K.-C. *see* Chang, T.-J.
Lee, M.C. *see* Chung, J.-K.
Léger, J. *see* Meas, T.
Leonetti, F. *see* Sbraccia, P.
Leonsson, M., Hulthe, J., Oscarsson, J., Johannsson, G., Wendelhag, I., Wikstrand, J. & Bengtsson, B.-Å. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors: 751
Leroy, J.P. *see* Bercovici, J.P.
Lévy-Marchal, C. *see* Meas, T.
Lewitt, M.S. *see* Unden, A.-L.
Liberman, B. *see* Antonini, S.R.R.
Liel, Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients: 523
Lin, J.-Y. *see* Chang, T.-J.
Lin, S.Y., Wang, Y.Y. & Sheu, W.H.-H. Increased serum leptin concentrations correlate with soluble tumour necrosis factor receptor levels in patients with cirrhosis: 805
Lindström, T. *see* Ekman, B.
Links, T.P. *see* Schaap, J.
Lip, W.V.D. *see* Arends, N.J.T.
Lissett, C.A., Murray, R.D. & Shalet, S.M. Timing of onset of growth hormone deficiency is a major influence on insulin-like growth factor I status in adult life: 35
Liu, R.-T. *see* Hsieh, C.-J.
Lobo, R.A. *see* Carmina, E.
Longini, M. *see* Massafra, C.
Lowe, D.G. *see* Janmohamed, S.
Lu, Y.-C. *see* Hsieh, C.-J.
Lucas, A. *see* Webb, S.M.
Lucas, T. *see* Webb, S.M.
Lupi, I. *see* Manetti, L.
Luton, J.-P. *see* Lamarre-Cliche, M.
Maccario, M. *see* Broglio, F.
Machado, H.R. *see* Antonini, S.R.R.
Machelon, V. *see* Bercovici, J.P.
Maciel, R.M.B. *see* Hauache, O.M.
Maia Jr, A.C.M. *see* Hauache, O.M.
Mancini, F.P *see* Vaccaro, O.
Manetti, L. *see* Bogazzi, F.
Manetti, L., Bogazzi, F., Brogioni, S., Grasso, L., Lupi, I., Genovesi, M., Cecconi, E., Gasperi, M. & Martino, E. Submandibular salivary gland volume is increased in patients with acromegaly: 97
Manganella, G. *see* Carella, C.
Maniati-Christidi, M. *see* Manoli, I.
Manoli, I., Kanaka-Gantenbein, Ch., Voutetakis, A., Maniati-Christidi, M. & Dacou-Voutetakis, C. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome: 669
Mantero, F. *see* Francucci, C.M.

Manzella, D., Carbonella, M., Ragno, E., Passariello, N., Grella, R. & Paolisso, G. Relationship between autonomic cardiac activity, β-cell function, anthropometrics and metabolic indices in type II diabetics: 259
Marazuela, M. *see* Ruíz-Giardín, J.M.
Martin, U. *see* Toescu, V.
Martina, V., Bruno, G.A., Origlia, C., Gaia, D., Trucco, F. & Pescarmona, G. Transdermal oestradiol replacement therapy enhances platelet constitutive nitric oxide synthase activity in postmenopausal women with type 2 diabetes mellitus: 371
Martínez, M.A. *see* Leal-Cerro, A.
Martino, E. *see* Bogazzi, F.
Martino, E. *see* Manetti, L.
Massafra, C., Gioia, D., De Felice, C., Muscettola, M., Longini, M. & Buonocore, G. Gender-related differences in erythrocyte glutathione peroxidase activity in healthy subjects: 663
Massi, F. *see* Francucci, C.M.
Mastorantonakis, S.E. *see* Efstathiou, S.P.
Masulli, M. *see* Vaccaro, O.
Matarese, G., Castelli-Gattinara, G., Cancrini, C., Bernardi, S., Romiti, M.L., Savarese, C., Di Giacomo, A., Rossi, P. & Racioppi, L. Serum leptin and $CD4^+$ T lymphocytes in HIV^+ children during highly active antiretroviral therapy: 643
Mauvais-Jarvis, F., Kulkarni, R.N. & Kahn, C.R. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance: 1
Mazzaferri, E.L. Gonadal damage from ^{131}I therapy for thyroid cancer, 313
Mazziotti, G. *see* Carella, C.
McCallum, R.W., Petrie, J.R., Dominiczak, A.F. & Connell, J.M.C. Growth hormone deficiency and vascular risk: 11
McIntyre, E.A. & Walker, M. Genetics of type 2 diabetes and insulin resistance: knowledge from human studies, 303
Meas, T., Chevenne, D., Thibaud, E., Léger, J., Cabrol, S., Czernichow, P. & Lévy-Marchal, C. Endocrine consequences of premature pubarche in post-pubertal Caucasian girls: 101
Medina, S. *see* Díez, J.J.
Meeran, K. *see* Turner, J.J.O.
Mellon, P.L. *see* Arroyo, A.
Mendonca, B.B. *see* Antonini, S.R.R.
Mersebach, H. *see* Sneppen, S.B.
Metcalfe, K. *see* Janmohamed, S.
Metherell, L. *see* Bjarnason, R.
Michel, L. *see* Rosière, A.
Micic, D. *see* Leal, A.
Minagawa, A., Iitaka, M., Suzuki, M., Yasuda, S., Kameyama, K., Shimada, S., Kitahama, S., Wada, S. & Katayama, S. A case of primary mucoepidermoid carcinoma of the thyroid: molecular evidence of its origin: 551
Ming-Chun K. *see* Ching-Jung H.
Minuto, F. *see* Giusti, M.
Mitromaras, A.G. *see* Efstathiou, S.P.
Mohan, U. *see* Blair, J.C.
Møller, N. *see* Nørrelund, H.
Monson, J.P. *see* Mukhopadhyay, B.
Monson, J.P. *see* Janmohamed, S.
Monson, J.P. *see* Kaltsas, G.A.
Monte, L.V.B. *see* Salvatori, R.
Moreira, A.C. *see* Antonini, S.R.R.
Morgenthaler, N.G., Nagata, A., Katayama, S., Bergmann, A. & Iitaka, M. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor: 193
Mori, K. *see* Nakagawa, Y.
Morris, D.G. *see* Kaltsas, G.A.
Morris, J.C. *see* Spitzweg, C.
Mountokalakis, T.D. *see* Efstathiou, S.P.
Mukherjee, J.J. *see* Kaltsas, G.A.
Mukhopadhyay, B., Sahdev, A., Monson, J.P., Besser, G.M., Reznek, R.H. & Chew, S.L. Pancreatic lesions in von Hippel–Lindau disease: 603
Murray, R.D. *see* Gilchrist, F.J.
Murray, R.D. *see* Lissett, C.A.
Muscettola, M. *see* Massafra, C.
Mushtaq, T. *see* Ahmed, S.F.
Musolino, N.R. *see* Glezer, A.
Nagata, A. *see* Morgenthaler, N.G.
Nakagawa, Y., Mori, K., Hoshikawa, S., Yamamoto, M., Ito, S. & Yoshida, K. Postpartum recurrence of Graves' hyperthyroidism can be prevented by the continuation of antithyroid drugs during pregnancy: 467
Netelenbos, J.C. *see* van Coeverden, S.C.C.M.
Nguyen, T. *see* Basaria, S.
Niepomniszcze, H. *see* Pitoia, F.
Nieschlag, E. *see* Eckardstein, S.V.
Nørrelund, H., Hansen, T.K., Ørskov, H., Hosoda, H., Kojima, M., Kangawa, K., Weeke, J., Møller, N., Christiansen, J.S. & Jørgensen, J.O.L. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin: 539
Nuttall, S.L. *see* Toescu, V.
Nyström, F.H. *see* Ekman, B.
O'Brien, P.E. *see* Dixon, J.B.
O'Dwyer, S.T. *see* Parkinson, C.
Obiols, G. *see* Webb, S.M.
Öhman, P.K. *see* Ekman, B.
Ong, K. *see* Yuen, K.
Origlia, C. *see* Martina, V.
Ørskov, H. *see* Hansen, T.K.
Ørskov, H. *see* Nørrelund, H.
Oscarsson, J. *see* Leonsson, M.

Osmond, C. *see* Kajantie, E.
Ovesen, L. *see* Knudsen, N.
Page, N.M. The endocrinology of pre-eclampsia: 413
Pal, K. *see* Basu, M.
Panagiotou, T.N. *see* Efstathiou, S.P.
Pantanetti, P. *see* Francucci, C.M.
Paolisso, G. *see* Manzella, D.
Paramo, C. *see* Leal, A.
Páramo, C. *see* Webb, S.M.
Park, D.J. *see* Chung, J.-K.
Park, Y.J. *see* Chung, J.-K.
Parkinson, C., Renehan, A.G., Ryder, W.D.J., O'Dwyer, S.T., Shalet, S.M. & Trainer, P.J. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly: 59
Passariello, N. *see* Manzella, D.
Patel, L. *see* Trueman, J.A.
Pei-Wen W. *see* Ching-Jung H.
Pereira, R.M.C. *see* Salvatori, R.
Pernasetti, F. *see* Arroyo, A.
Perrild, H. *see* Knudsen, N.
Perry, L.A. *see* Blair, J.C.
Pescarmona, G. *see* Martina, V.
Petrie, J.R. *see* McCallum, R.W.
Phillips III, J.A. *see* Salvatori, R.
Phillips, D.I.W. *see* Kajantie, E.
Picó, A. *see* Boix, E.
Picó, A. *see* Webb, S.M.
Pinchera, A. *see* Bogazzi, F.
Pinedo, R. *see* Boix, E.
Pitoia, F. & Niepomniszcze, H. Tumour growth after recombinant human TSH: 301
Plouin, P.-F. *see* Lamarre-Cliche, M.
Plowman, P.N. *see* Janmohamed, S.
Plowman, P.N. *see* Kaltsas, G.A.
Popovic, V. *see* Leal, A.
Popp-Snijders, C. *see* van Coeverden, S.C.C.M.
Prasad, R. *see* Basu, M.
Price, D.A. *see* Trueman, J.A.
Prieto, L. *see* Webb, S.M.
Prodam, F. *see* Broglio, F.
Pulaski, K. *see* Fairfield, W.P.
Racioppi, L. *see* Matarese, G.
Ragno, E. *see* Manzella, D.
Rago, T. *see* Bogazzi, F.
Rajan, B. *see* Brada, M.
Rajanayagam, O. *see* Blair, J.C.
Ranke, M.B. *see* Doherty, C.P.
Ranke, M.B. *see* Yuen, K.
Rasmuson, T., Damber, L., Johansson, L., Johansson, R. & Larsson, L.-G. Increased incidence of parathyroid adenomas following X-ray treatment of benign diseases in the cervical spine in adult patients: 731
Renehan, A.G. *see* Parkinson, C.
Reznek, R.H. *see* Mukhopadhyay, B.
Riccardi, G. *see* Vaccaro, O.
de Ridder, C.M. *see* van Coeverden, S.C.C.M.
Robben, S.G.F. *see* Arends, N.J.T.
Roberts, N. *see* Saravanan, P.
Robinson, M. *see* Alexander, E.K.
Robinson, S. *see* Johnston, D.G.
Rocha, A.J. *see* Hauache, O.M.
Roelants, V. *see* Rosière, A.
Romero, J. *see* Ruíz-Giardín, J.M.
Romijn, J.A. *see* Schaap, J.
Romiti, M.L. *see* Matarese, G.
Ronald Kahn, C. *see* Mauvais-Jarvis, F.
Roos, J.C. *see* van Coeverden, S.C.C.M.
Rosberg, S. *see* Bjarnason, R.
Rose, S.J. *see* Bjarnason, R.
Rosenfeld, R. *see* Yuen, K.
Rosenson, R.S. *see* Basaria, S.
Rosière, A., Ernst, Y.J., Roelants, V., Vander Borght, T., Michel, L. & Donckier, J.E. Intraoperative gamma probe detection of insulinoma in an elderly patient with pancreatic cystic lesions: 547
Rossi, P. *see* Matarese, G.
Rotondi, M. *see* Carella, C.
Roudaut, N. *see* Bercovici, J.P.
Rue-Tsuan L. *see* Ching-Jung H.
Ruffa, G. *see* Vaccaro, O.
Ruíz-Giardín, J.M., Cremades, C., Romero, J. & Marazuela, M. Insulin autoimmune syndrome in a patient with viral hepatitis C: 411
Ryder, W.D.J. *see* Parkinson, C.
Sabatino, L. *see* Vaccaro, O.
Sahdev, A. *see* Mukhopadhyay, B.
Şahiner, Ş. *see* Erten, Y.
Salgado, L.R. *see* Glezer, A.
Salvatori, R., Aguiar-Oliveira, M.H., Monte, L.V.B., Hedges, L., Santos, N.L., Pereira, R.M.C. & Phillips III, J.A. Detection of a recurring mutation in the human growth hormone-releasing hormone receptor gene: 77
Santeusanio, F. *see* Laureti, S.
Santini, L. *see* Carella, C.
Santos, N.L. *see* Salvatori, R.
Saravanan, P., Chau, W.-F., Roberts, N., Vedhara, K., Greenwood, R. & Dayan, C.M. Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study: 577
Sarkar, M.A.K. *see* Doherty, C.P.
Savage, M.O. *see* Bjarnason, R.

Savage, M.O. *see* Blair, J.C.
Savarese, C. *see* Matarese, G.
Sawhney, R.C. *see* Basu, M.
Sbraccia, P., D'Adamo, M., Leonetti, F., Buongiorno, A., Silecchia, G., Sole Basso, M., Tamburrano, G., Lauro, D., Federici, M., Di Daniele, N. & Lauro, R. Relationship between plasma free fatty acids and uncoupling protein-3 gene expression in skeletal muscle of obese subjects: *in vitro* evidence of a causal link: 199
Schaap, J., Eustatia-Rutten, C.F.A., Stokkel, M., Links, T.P., Diamant, M., van der Velde, E.A., Romijn, J.A. & Smit, J.W.A. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma? 117
Schettini, G. *see* Giusti, M.
Schlumberger, M. *see* Faggiano, A.
Schmidt, A. *see* Eckardstein, S.V.
Schmidt, A., Chakravarty, A., Brommer, E., Fenne, B.D., Siebler, T., De Meyts, P. & Kiess, W. Growth failure in a child showing characteristics of Seckel syndrome: possible effects of IGF-I and endogenous IGFBP-3: 293
Schobel, H. *see* Seifarth, C.
Schönau, E. *see* Kamp, G.A.
Scirè, G. *see* Cianfarani, S.
Seckl, J.E.R. *see* Blackhurst, G.
Seifarth, C., Trenkel, S., Schobel, H., Hahn, E.G. & Hensen, J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism: 457
Selvamurthy, W. *see* Basu, M.
Sensebe, L. *see* Bercovici, J.P.
Serafini, P. *see* Glezer, A.
Sesmilo, G. *see* Fairfield, W.P.
Shakur, M.S. *see* Doherty, C.P.
Shalet, S.M. *see* Gilchrist, F.J.
Shalet, S.M. *see* Gleeson, H.K.
Shalet, S.M. *see* Lissett, C.A.
Shalet, S.M. *see* Parkinson, C.
Shan-Tair W. *see* Ching-Jung H.
Sharkey, N. *see* Whipple, T.
Sheu, W.H.-H. *see* Lin, S.Y.
Shih-Chen T. *see* Ching-Jung H.
Shimada, S. *see* Minagawa, A.
Siebler, T. *see* Schmidt, A.
Silecchia, G. *see* Sbraccia, P.
Simoni, M. *see* Eckardstein, S.V.
Smit, J.W.A. *see* Schaap, J.
Sneppen, S.B., Mersebach, H., Ullum, H. & Feldt-Rasmussen, U. Immune function during GH treatment in GH-deficient adults: an 18-month randomized, placebo-controlled, double-blinded trial: 787
So, Y. *see* Chung, J.-K.
Sole Basso, M. *see* Sbraccia, P.
Sørensen, H.H. *see* Hansen, T.K.
Sorvillo, F. *see* Carella, C.
Soto, A. *see* Leal-Cerro, A.
Souza, A.H.O. *see* Gleeson, H.K.
Spadoni, G.L. *see* Cianfarani, S.
Spaziante, R. *see* Giusti, M.
Spitzweg, C. & Morris, J.C. The sodium iodide symporter: its pathophysiological and therapeutic implications: 559
Staniec, M. *see* Alexander, E.K.
Statham, P.F.X. *see* Blackhurst, G.
Stavrou, S. *see* Fairfield, W.P.
Stokkel, M. *see* Schaap, J.
Strachan, M.W. *see* Blackhurst, G.
Stratakis, C.A. *see* Kaltsas, G.A.
Suzuki, M. *see* Minagawa, A.
Swords, F.M. *see* Kaltsas, G.A.
Tada, H. *see* Izumi, Y.
Tai, T.-Y. *see* Chang, T.-J.
Takano, T. *see* Izumi, Y.
Talbot, M. *see* Faggiano, A.
Tamburrano, G. *see* Sbraccia, P.
Tassone, F. *see* Broglio, F.
Tatsumi, K.-I. *see* Izumi, Y.
Thakker, R.V. *see* Turner, J.J.O.
Thibaud, E. *see* Meas, T.
Tillmann, V. *see* Trueman, J.A.
Toescu, V., Nuttall, S.L., Martin, U., Kendall, M.J. & Dunne, F. Oxidative stress and normal pregnancy: 609
Tolunay, O. *see* Erten, Y.
Tomer, Y. *see* Ban, Y.
Tondinelli, T. *see* Cianfarani, S.
Torres, E. *see* Leal, A.
Trainer, P.J. *see* Parkinson, C.
Traish, D. *see* Brada, M.
Trenkel, S. *see* Seifarth, C.
Trucco, F. *see* Martina, V.
Trueman, J.A., Tillmann, V., Cusick, C.F., Foster, P., Patel, L., Hall, C.M., Price, D.A. & Clayton, P.E. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle: 223
Tsai, M.-H. *see* Chang, T.-J.
Tsiakou, A.G. *see* Efstathiou, S.P.
Tsioulos, D.I. *see* Efstathiou, S.P.
Tucker, P. *see* Ahmed, S.F.
Tung, S.-C. *see* Hsieh, C.-J.
Tuominen, J. *see* Kajantie, E.
Turner, H.E. *see* García de la Torre, N.

Turner, J.J.O., Wren, A.M., Jackson, J.E., Thakker, R.V. & Meeran, K. Localization of gastrinomas by selective intra-arterial calcium injection: 821
Tuvemo, T. *see* Halldin, M.U.
Ullum, H. *see* Sneppen, S.B.
Unden, A.-L., Elofsson, S., Knox, S., Lewitt, M.S. & Brismar, K. IGF-I in a normal population: relation to psychosocial factors: 793
Vaccaro, O., Mancini, F.P, Ruffa, G., Sabatino, L., Iovine, C., Masulli, M., Colantuoni, V. & Riccardi, G. Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) γ2 gene in healthy individuals: 481
Vahl, N. *see* Abrahamsen, B.
van der Velde, E.A. *see* Schaap, J.
Van Tijn, D.A. *see* Bakker, B.
Van Bruggen, M. *see* Bakker, B.
Vander Borght, T. *see* Rosière, A.
Vasilyev, V.V. *see* Arroyo, A.
Vedhara, K. *see* Saravanan, P.
Vieira, J.G. *see* Glezer, A.
Vieira, J.G.H. *see* Hauache, O.M.
Voutetakis, A. *see* Manoli, I.
Vulsma, T. *see* Bakker, B.
Wada, S. *see* Minagawa, A.
Wade, J.C. *see* Doherty, C.P.
Walker, B.R., Irving, R.J., Andrew, R. & Belton, N.R. Contrasting effects of intrauterine growth retardation and premature delivery on adult cortisol secretion and metabolism in man: 351
Walker, M. *see* McIntyre, E.A.
Wallace, A.M. *see* Ahmed, S.F.
Wang, P.-W. *see* Hsieh, C.-J.
Wang, S.-T. *see* Hsieh, C.-J.
Wang, Y.Y. *see* Lin, S.Y.
Wass, J.A.H. *see* garcía de la Torre, N.
Webb, S.M., Prieto, L., Badia, X., Albareda, M., Catalá, M., Gaztambide, S., Lucas, T., Páramo, C., Picó, A., Lucas, A., Halperin, I., Obiols, G. & Astorga, R. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties: 251
Weeke, J. *see* Nørrelund, H.
Weetman A.P. Thyroxine treatment in biochemically euthyroid but clinically hypothyroid individuals: 25
Weisinger, J.R. *see* Lanes, R.
Wen-Yen C. *see* Ching-Jung H.
Wendelhag, I. *see* Leonsson, M.
Westin, G. *see* Correa, P.
Whipple, T., Sharkey, N., Demers, L. & Williams, N. Leptin and the skeleton: 701
Wiedijk, B.M. *see* Bakker, B.
Wieringa, G.E. *see* Gleeson, H.K.
Wijeyaratne, C.N., Balen, A.H., Barth, J.H. & Belchetz, P.E. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? 343
Wikstrand, J. *see* Leonsson, M.
Williams, A.J. *see* Forsling, M.L.
Williams, D.M. *see* Ahmed, S.F.
Williams, N. *see* Whipple, T.
Wirén, L., Boguszewski, C.L. & Johannsson, G. Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy: 235
Wit, J.M. *see* Kamp, G.A.
Wittert, G.A. *see* Keogh, M.A.
Wood, D.F. *see* Janmohamed, S.
Wood, P.J. *see* Kajantie, E.
Wren, A.M. *see* Turner, J.J.O.
Yamamoto, M. *see* Nakagawa, Y.
Yasuda, S. *see* Minagawa, A.
Yen, S.S.C. *see* Arroyo, A.
Yoshida, K. *see* Nakagawa, Y.
Yuen, K., Cook, D., Ong, K., Chatelain, P., Fryklund, L., Gluckman, P., Ranke, M.B., Rosenfeld, R. & Dunger, D. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults: 333
Yung-Chuang L. *see* Ching-Jung H.
Zacharos, I.D. *see* Efstathiou, S.P.
Zito, G. *see* Carella, C.
Zwinderman, A.H. *see* Kamp, G.A.

Clinical Endocrinology (2002) **57**, 845–851

Subject Index to Volume 57

Acne
  treatment with antiandrogens 231
Acromegaly
  effects of GH receptor antagonist on bone markers 385
  health-related quality of life questionnaire 251
  influence of gender and age on GH and IGF-I 59
  salivary gland enlargement in 97
  thyroid vascularity in 65
ACTH
  low-dose test, in preclinical adrenal autoimmunity 677
  secretion by pituitary adenomas 657
Adrenal autoimmunity
  preclinical, low-dose ACTH test 677
Adrenalectomy
  chromogranin A and 41
Adrenal incidentaloma
  BMD and bone turnover 587
Age
  gestational, foetal programming and adult cortisol 635
  gestational, MRI pituitary studies and GHD 719
  influence on GH and IGF-I in acromegaly 59
Aldosterone
  influence of antihypertensive medication 457
  in low-dose ACTH test 677
Aldosteronism
  primary, and antihypertensive medication 457
Amino acids
  infusion, and necrolytic migratory erythema (Case report) 825
Androgens
  predictive measure in obesity 769
  therapy and plasma viscosity 209
Angiogenesis
  effects of somatostatin analogues (Review) 425
Antiandrogens
  in treatment of acne 231
Anticholinergic therapy
  insulin sensitivity and lipolysis in type 1 diabetes 735
Antihypertensive medication
  in diagnosis of essential hypertension 457
Antineutrophil cytoplasmic antibody
  after propylthiouracil therapy (Letter) 699
Antithyroglobulin antibody
  after thyroid ablation 215
Antithyroid drugs
  in pregnancy 467
Arginine
  effects on GH-releasing activity of ghrelin 265
Autoimmune disease
  insulin autoimmune syndrome and hepatitis C virus (Letter) 411
  preclinical adrenal 677
Autoimmune disease
  thyroid, influence of HLA genes 81

Birth size
  foetal programming and adult cortisol 635
Body mass index
  in CAH 669
  GHD and cardiovascular risk factors 751
Bone
  BMD and bone metabolism in children on GH therapy 725
  BMD and bone turnover in hypercortisolism 587
  effects of GH receptor antagonist on bone markers in acromegaly 385
  effects of glucocorticoids on turnover 185
  leptin and the skeleton (Review) 701
  metabolism markers and mass in puberty 107
  remodelling markers and cytokines in hyperthyroidism 125
  restoring mass in adult-onset GHD 273
  turnover, malnutrition and catch-up growth 391

Cabergoline
  effect on thyroid function in hyperprolactinaemia (Letter) 699
CAH
  growth pattern and final height 669
Calcium gluconate
  localization of gastrinomas (Case report) 821
Carcinoid tumour
  thymic, secretion of GHRH (Case report) 131
Cardiac activity
  autonomic, in type II diabetes 259
Cardiovascular disease
  cerebrovascular mortality and pituitary adenomas 713
  GHD and vascular risk (Review) 11
  mechanisms of vascular disease in hypopituitarism (Commentary) 159
  oxidative stress and normal pregnancy 609
  risk factors in GHD with hypopituitarism 751
  transdermal oestrogen and NOS in type 2 diabetes 371
Catecholamine
  effects of slow-release octreotide in phaeochromocytoma 629

© 2002 Blackwell Publishing Ltd

C-cell hyperplasia
galactin-3 in 813
Cerebrovascular accidents
pituitary adenomas and 713
Chemotherapy (combined)
neuroendocrine tumours 169
suprasellar germ cell tumours 487
Children
adult cortisol and premature babies 351
bone metabolism markers and bone mass in puberty 107
effects of glucocorticoids on growth and bone turnover 185
GH dose-response and idiopathic short stature 315
GH therapy, BMD and bone metabolism 725
leptin and $CD4^+$ T lymphocytes during HAART 643
neonatal thyrotoxicosis in RTH (Case report) 405
with partial GH insensitivity 357
pituitary MRI studies and GHD 719
premature pubarche in Caucasian girls 101
Seckel syndrome and growth failure (Case report) 293
suppression of puberty with long-acting gosarelin 223
Chromogranin A
effects of slow-release octreotide in phaeochromocytoma 629
secretion in humans 41
Cirrhosis
leptin and TNF in 805
Collagen
turnover, malnutrition and catch-up growth 391
Contraception
male hormonal, and CAG repeats 647
oral, goitre prevalence among users 71
Cortisol
adult, and foetal programming 635
adult secretion, and metabolism in premature babies 351
C-peptide
cardiac autonomic activity in type II diabetes 259
Cushing's disease/syndrome
BMD and bone turnover in 587
somatostatin, GHRH and GH secretion 745
Cyproterone acetate
in treatment of acne 231
Cytokines
bone remodelling markers in hyperthyroidism 125
Hodgkin's disease and thyroiditis (Case report) 691
TNF-α and thyroid dysfunction 515

Dexamethasone
effects on linear growth and bone turnover 185
DHEA
in low-dose ACTH test 677
Diabetes
mortality prediction model in ketoacidosis 595
type 1, insulin sensitivity and lipolysis in adolescents 735
type 2, and β2-adrenoreceptor 685
type 2, C-peptide and cardiac autonomic activity 259
type 2, effects of transdermal oestrogen on NOS 371
type 2, and insulin resistance, genetic studies (Review) 303
type 2, mitochondrial DNA mutations (Letter) 141, 142

Erythrocytes
glutathione peroxidase activity and gender 663

Fatty acids
infusion, and necrolytic migratory erythema (Case report) 825
see also Free fatty acids
Finasteride
in treatment of acne 231
5-Fluorouracil
combination therapy of neuroendocrine tumours 169
Flutamide
in treatment of acne 231
Foetal programming
adult cortisol and 635
Free fatty acids
effects on GH-releasing activity of ghrelin 265
in obesity 199
Pro12Ala polymorphism of PPAR γ2 gene and 481

Galectin-3
in thyroid carcinoma 813
Gamma probe
intraoperative detection of insulinoma (Case report) 547
Gastrinomas
localization by intra-arterial calcium injection (Case report) 821
Gender
GHD and cardiovascular risk factors 751
influence on GH and IGF-I in acromegaly 59
see also Men, Women
Genetics
β2-adrenoreceptor in type 2 diabetes 685
CAG repeats and hormonal male contraception 647
free fatty acids and uncoupling protein-3 gene in obesity 199
Gcm2 in primary hyperparathyroidism 501
glucocorticoid receptor gene polymorphisms 657
HLA genes and autoimmune thyroid disease 81
knockout models of insulin resistance (Review) 1
maternal infertility in RTH (Case report) 405

mitochondrial DNA mutations in type 2 diabetes (Letters) 141, 142
mucoepidermoid carcinoma of thyroid (Case report) 551
neonatal thyrotoxicosis in RTH (Case report) 405
PRKAR1A gene in sporadic pituitary tumours 443
Pro12Ala polymorphism of PPAR γ2 gene 481
PROP1 deficiency and GHD (Commentary) 157
PROP1 mutation (Case report) 283
recurring *GHRHR* mutation 77
sodium iodide symporter (Review) 559
type 2 diabetes and insulin resistance (Review) 303
Germ cell tumours
suprasellar, diagnosis and management 487
GH
dose-response and idiopathic short stature 315
effects on ghrelin in human plasma 539
effects on renin-angiotensin-aldosterone system 473
impact of GHBP on estimates and pharmacokinetics 779
influence of gender and age in acromegaly 59
insufficiency, tests for diagnosis 161
partial insensitivity in children 357
receptor antagonist, and bone markers in acromegaly 385
releasing activity of ghrelin 265
secretion by pituitary adenomas, and leptin 449
secretion in Cushing's syndrome 745
stimulation tests in diagnosis of insufficiency 161
therapy, in pregnancy 235
therapy, BMD and bone metabolism in children 725
therapy, effect on quality of life 363
therapy, effects on immune function 787
therapy, metabolic effects of low and high doses 333
therapy, optimum dose for restoring bone mass 273
GHBP
impact on GH estimates and pharmacokinetics 779
GHD
adult-onset, and optimum dose of GH 273
diagnostic tests for adults 377
effect on quality of life 363
effects of GH therapy on immune function 787
GH therapy in pregnancy 235
height and PROP1 deficiency (Commentary) 157
hypopituitarism and cardiovascular risk factors 751
IGF-I status in 35
lipid profiles in 89
metabolic effects of low and high GH doses 333
MRI studies in children 719
vascular risk and (Review) 11
Ghrelin
GH-releasing activity 265
immunoreactivity in human plasma 539
GHRH
GH secretion in Cushing's syndrome 745
receptor, recurring *GHRHR* mutation 77
secretion by thymic carcinoid tumour (Case report) 131
tests for diagnosis of GHD in adults 377
GHRP-6
in tests for diagnosis of GHD in adults 377
Glomerulonephritis
propylthiouracil therapy and (Letter) 699
Glucagonoma syndrome
treatment of necrolytic migratory erythema (Case report) 825
Glucocorticoids
as prophylaxis against acute mountain sickness 761
receptor gene polymorphisms 657
Glucose
effects on GH-releasing activity of ghrelin 265
Glutathione peroxidase activity
gender-related differences 663
GnRH
gonadotrophin response to long-acting gosarelin 223
Goitre
oral contraceptive use and 71
recurrence, and iodized salt prophylaxis 507
Gonadotrophins
CAG repeats and hormonal male contraception 647
response to long-acting gosarelin 223
Gonads
damage from radioiodine therapy (Commentary) 313
Gosarelin
long-acting, gonadotrophin response 223
Graves' disease
antithyroid drugs in pregnancy 467
complications of propylthiouracil therapy (Letter) 699
detection of low titre TBII 193
differential diagnosis of thyrotoxicosis 51
Growth
catch-up, and malnutrition 391
effects of glucocorticoids 185
failure, in Seckel syndrome (Case report) 293
intrauterine retardation, and cortisol 351
pattern in CAH 669

HAART
leptin and $CD4^+$ T lymphocytes in 643
Height
final, in CAH 669
GHD and PROP1 deficiency (Commentary) 157
velocity, in diagnosis of GH insufficiency 161
see also Short stature

Hepatitis C virus infection
insulin autoimmune syndrome and (Letter) 411
HIV infection
leptin and CD4$^+$ T lymphocytes during HAART 643
HLA
influence on autoimmune thyroid disease 81
Hodgkin's disease
cytokines and thyroiditis (Case report) 691
Hyperandrogenism
treatment of acne with antiandrogens 231
Hypercortisolism
BMD and bone turnover in 587
foetal programming and adult cortisol 635
Hyperinsulinaemia
predictive measure in obesity 769
Hyperparathyroidism, primary
Gcm2 underexpression and 501
localization of enlarged parathyroid glands 241
management (Review) 145
Hyperprolactinaemia
effect of cabergoline on thyroid function (Letter) 699
pitfalls in pituitary diagnosis (Case report) 135
screening and pituitary imaging 327
Hypertension, essential
antihypertensive medication in differential diagnosis 457
chromogranin A and 41
Hyperthyroidism
antithyroid drugs in pregnancy 467
bone remodelling markers and cytokines 125
TNF-α and 515
Hypocortisolism
foetal programming and adult cortisol 635
Hypopituitarism
GHD and cardiovascular risk factors 751
mechanisms of vascular disease in (Commentary) 159
Hypothalamic-pituitary-adrenal (HPA) axis
foetal programming and adult cortisol 635
Hypothyroidism
congenital, and thyroxine supplementation 529
psychological well-being in patients 577
(Commentary) 575
thyroxine treatment in (Commentary) 25
TNF-α and 515
Hypoxia
glucocorticoids and acute mountain sickness 761

IGFBP
IGFBP-2 and IGFB-3, malnutrition and catch-up growth 391
IGFBP-3, Seckel syndrome and growth failure (Case report) 293
IGF-I
in diagnosis of GH insufficiency 161
GH dose-response in idiopathic short stature 315
GH receptor antagonist and bone markers in acromegaly 385
influence of gender and age in acromegaly 59
malnutrition and catch-up growth 391
relation to psychosocial factors 793
Seckel syndrome and growth failure (Case report) 293
status in GHD 35
Immune function
effects of GH therapy in GHD adults 787
Incidentaloma, adrenal
BMD and bone turnover 587
Infertility
maternal, in RTH (Case report) 405
Insulin
autoimmune syndrome and hepatitis C virus (Letter) 411
knockout models of resistance (Review) 1
resistance, and diabetes type 2, genetic studies (Review) 303
resistance, in PCOS 343
resistance, predictive measure in obesity 769
sensitivity, in type 1 diabetes 735
Insulinoma
intraoperative detection (Case report) 547
Intima-media thickness
in GHD with hypopituitarism 751
Intrauterine growth retardation
effects on cortisol 351
Iodine
iodized salt prophylaxis for goitre 507
see also Radioiodine

Ketoacidosis, diabetic
mortality prediction model 595
Knockout models
insulin resistance (Review) 1

Leptin
CD4$^+$ T lymphocytes during HAART 643
in cirrhosis 805
GH-secreting pituitary adenomas and 449
in sequential thyroid function change 29
skeleton and (Review) 701
Levothyroxine
suppressive treatment of thyroid nodules 621
Lipids
profiles in GHD 89
Lipolysis
in type 1 diabetes 735

Lomustine
combination chemotherapy of neuroendocrine tumours 169

Macroprolactinaemia
screening and pituitary imaging studies 327
Malnutrition
catch-up growth and 391
Melatonin
effects on stimulated neurohypophysial hormone release 615
Men
CAG repeats and hormonal contraception 647
glutathione peroxidase activity 663
Metabolism
BMD and bone turnover in hypercortisolism 587
bone, in children on GH therapy 725
cortisol, in adults with premature delivery 351
effects of low and high GH doses 333
leptin and the skeleton (Review) 701
Metanephrine
effects of slow-release octreotide in phaeochromocytoma 629
Mortality prediction model
in diabetic ketoacidosis 595
Mountain sickness, acute
glucocorticoids as prophylaxis 761
MRI
pituitary region, and GHD 719
Mucoepidermoid carcinoma
of thyroid (Case report) 551

Neck circumference
predictive value in obesity 769
Necrolytic migratory erythema
treatment in glucagonoma syndrome (Case report) 825
Neuroendocrine tumours
combination chemotherapy 169
Neurohypophysial hormone release
stimulated, and melatonin 615
Nitric oxide synthase (NOS)
effects of transdermal oestrogen in type 2 diabetes 371

Obesity
free fatty acids and uncoupling protein-3 gene 199
predictive measure of raised insulin and androgens 769
Octreotide
effects on TSH-secreting adenoma in pregnancy (Case report) 401
slow-release, and phaeochromocytoma 629
Oestrogen
therapy, and goitre 71
transdermal, and NOS in type 2 diabetes 371
17OHP
in low-dose ACTH test 677
Oral contraceptives
CAG repeats and male contraception 647
goitre prevalence among users 71
Oxidative stress
normal pregnancy and 609
Oxytocin
effects of melatonin 615

Pancreas
intraoperative detection of insulinoma (Case report) 547
lesions in von Hippel–Landau disease 603
Parathyroid adenomas
after radiotherapy in adults 731
Gcm2 underexpression and 501
Phaeochromocytoma
effects of slow-release octreotide 629
Pirenzepine therapy
in type 1 diabetes 735
Pituitary
MRI studies and GHD 719
Pituitary adenomas
ACTH-secreting 657
cerebrovascular mortality and 713
GH-secreting, and leptin 449
glucocorticoid receptor gene polymorphisms 657
sporadic, and protein kinase A 443
TSH-secreting, effects of pregnancy and octreotide (Case report) 401
Pituitary disease
combined pituitary hormone deficiency (Case report) 283
macroprolactinaemia and pituitary imaging 327
pitfalls in diagnosis (Case report) 135
Polycystic ovary syndrome (PCOS)
among South Asians and Caucasians 343
PPAR γ2 gene
Pro12Ala polymorphism and free fatty acids 481
Prednisolone
effects on linear growth and bone turnover 185
Pre-eclampsia
endocrinology (Review) 413
Pregnancy
antithyroid drugs in 467
effects on TSH-secreting adenoma (Case report) 401
endocrinology of pre-eclampsia (Review) 413
GH therapy in 235
normal, and oxidative stress 609

Propylthiouracil
complications of therapy (Letter) 699
Psychological well-being
thyroxine therapy and 577 (Commentary) 575
Psychosocial factors
role of IGF-I 793
Pubarche
premature, in Caucasian girls 101
Puberty
absent, and combined pituitary hormone deficiency (Case report) 283
bone metabolism markers and bone mass in 107
pattern in CAH 669
precocious, suppression with gosarelin 223
Quality of life
GHD and GH therapy in adults 363
health-related, in acromegaly 251
Questionnaire
quality of life in acromegaly 251

Radioiodine therapy
preparation for administration 523
gonadal damage and (Commentary) 313
in non-iodine accumulating thyroid carcinoma 117
Radiotherapy
combined therapy of suprasellar germ cell tumours 487
parathyroid adenomas and 731
Renin-angiotensin-aldosterone system
antihypertensive medication and primary aldosteronism 457
effects of GH on 473
RTH
neonatal thyrotoxicosis and maternal infertility in (Case report) 405

Salivary gland
enlargement in acromegaly 97
Scintigraphy
intraoperative detection of insulinoma (Case report) 547
localization of enlarged parathyroid glands 241
Screening
macroprolactinaemia and pituitary imaging 327
Seckel syndrome
growth failure in (Case report) 293
Short stature
GH dose-response relationships 315
GH therapy, BMD and bone metabolism 725
MRI pituitary studies in children 719
Skeletal muscle
in obesity 199
Skeleton
leptin and (Review) 701
Sodium iodide symporter (NIS) (Review) 559
Somatostatin
antiangiogenic effects of analogues (Review) 425
effects on ghrelin in human plasma 539
withdrawal, and GH secretion in Cushing's syndrome 745
TBII (thyrotropin-binding inhibitor immunoglobulin)
detection in Graves' disease 193
Testosterone
therapy, and plasma viscosity 209
Thymic carcinoid tumour
secretion of GHRH (Case report) 131
Thyroid carcinoma
antithyroglobulin antibody after ablation 215
galectin-3 in 813
non-iodine accumulating, and radioiodine therapy 117
preparation for radioiodine administration 523
primary mucoepidermoid (Case report) 551
radioiodine therapy and gonadal damage (Commentary) 313
tumour growth after human recombinant TSH (Letter) 301
Thyroid function
effect of cabergoline in hyperprolactinaemia (Letter) 699
influence of HLA genes 81
leptin in sequential function change 29
levothyroxine treatment of nodules 621
sodium iodide symporter (Review) 559
thyroid hormone resistance *see* RTH
TNF-α and 515
in treatment of congenital hypothyroidism 529
vascularity in acromegaly 65
Thyroiditis, fibrous
cytokines and Hodgkin's disease (Case report) 691
Thyrotoxicosis
destruction-induced, differential diagnosis 51
neonatal, in RTH (Case report) 405
Thyroxine therapy
in congenital hypothyroidism 529
in euthyroid individuals (Commentary) 25
iodized salt prophylaxis and 507
psychological well-being and 577 (Commentary) 575
T-lymphocytes
$CD4^+$, during HAART 643
TNF
in cirrhosis 805
TNF-α and thyroid dysfunction 515
Triiodothyronine (T3)
in treatment of congenital hypothyroidism 529

TSH
in levothyroxine treatment of thyroid nodules 621
in preparation for radioiodine administration 523
recombinant human, receptor assay 193
recombinant human, tumour growth after (Letter) 301
secretion by pituitary adenoma, in pregnancy (Case report) 401
in treatment of congenital hypothyroidism 529
Tumours
growth after human recombinant TSH (Letter) 301
see also Neuroendocrine tumours, specific tumours

Ultrasonography
localization of enlarged parathyroid glands 241
Uncoupling protein-3
gene expression in obesity 199

Vascular disease
mechanisms in hypopituitarism (Commentary) 159
Vascularity
thyroid, in acromegaly 65
Vascular risk
GHD and (Review) 11
Vasculitis
propylthiouracil therapy and (Letter) 699
Vasopressin
effects of melatonin 615
Viscosity, plasma
androgen therapy in postmenopausal women 209
von Hippel–Landau disease
pancreatic lesions in 603

Weight
loss, and obesity surgery 769
Well-being
IGF-I and psychosocial factors 793
thyroxine therapy and 577 (Commentary) 575
West syndrome
mitochondrial diabetes and (Letter) 142
Women
androgen therapy and plasma viscosity 209
antiandrogen treatment of acne 231
antithyroid drugs in pregnancy 467
BMD and bone turnover in hypercortisolism 587
effects of pregnancy and octreotide on TSH-secreting adenoma (Case report) 401
endocrinology of pre-eclampsia (Review) 413
GH therapy in pregnancy 235
glutathione peroxidase activity 663
oral contraceptives and goitre 71
oxidative stress and normal pregnancy 609
raised insulin and androgens in obesity 769
transdermal oestrogen and NOS in type 2 diabetes 371

X-ray *see* Radiotherapy

Zinc
supplementation, malnutrition and catch-up growth 391
Zoladex-LA
gonadotrophin response 223